Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Provided herein are AAV capsid polypeptides comprising peptide modifications relative to the wild-type AAV6 polypeptide that, when present in the capsid of an AAV vector, can facilitate homology directed repair (HDR)-mediated gene editing of human T cells. Also provided are AAV vectors comprising the capsid polypeptides, nucleic acid vectors comprising the encoding nucleic acid molecules, and host cells comprising the vectors, as well as methods of use of such AAV vectors, nucleic acid vectors and host cells.

Abstract: The present disclosure relates generally to modified adeno-associated virus (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells.

Abstract: Provided herein are methods for identifying novel cap genes suitable for vectorization, utilizing selection based on homologous recombination-mediated editing of a distinct genetic basis. Also provided is the selection and production of AAV vectors that can facilitate homologous recombination-mediated gene editing in a host cell or tissue of choice. Also provided are replication-incompetent AAV and AAV libraries for use in the methods, and nucleic acid molecules to generate the replication-incompetent AAV particles and AAV libraries.

Abstract: The present disclosure relates generally to modified adeno-associated virus (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells.

Abstract: The present disclosure relates generally to adeno-associated vims (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells. The disclosure includes AAV capsid polypeptides comprising a peptide modification in variable region 8 (VR VIII), where the peptide modification comprises a 7 amino acid insertion.

Abstract: The present disclosure relates generally to adeno-associated virus (AAV) capsid polypeptides and encoding nucleic acid molecules. The disclosure also relates to AAV vectors comprising the capsid polypeptides, and nucleic acid vectors (e.g. plasmids) comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells.

Abstract: The present disclosure relates generally to methods and adeno-associated virus (AAV) vectors for in vivo transduction. The disclosure is directed to methods for producing modified AAV capsid polypeptides and AAV vectors that are suitable for transduction of cells in vivo, and methods for screening AAV vectors. The disclosure also relates to adeno-associated virus (AAV) capsid polypeptides and encoding nucleic acid molecules, AAV vectors comprising the capsid polypeptides, and nucleic acid vectors comprising the encoding nucleic acids molecules, as well as to host cells comprising the vectors. The disclosure also relates to methods and uses of the polypeptides, encoding nucleic acids molecules, vectors and host cells.

Abstract: The present disclosure relates generally to nucleic acid molecules and methods for identifying AAV vectors with desirable properties, including nucleic acid molecules and methods useful for identifying novel cap genes for vectorization, production of AAV vectors and AAV libraries.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: The invention provides compositions and methods for the treatment or prevention of disease, including, for example, ?-thalassemia, anemias (e.g., sickle cell anemia) and other hemoglobinopathologies.

Abstract: The continuously variable electromagnetic transmission comprises a commutator-less, axial flux dynamoelectric machine (3) provided with an input shaft (2) and an output shaft (4), and means (20) for controlling and supplying electric power at a variable frequency to said machine. The dynamoelectric machine comprises a stator (16), a first rotor (12) which is connected to the input shaft, and a second rotor (15) which is connected to the output shaft and arranged in such a way that it can interact with the first rotor and the stator, whereby the two rotors and the stator are formed by discoid elements. The transmission comprises means for axially displacing at least one of the discoid elements in order to modify the width of the axial air gap between said element and an adjacent discoid element, whereby the magnetic field can be regulated by variations in said gap and the two rotors can be mechanically coupled to each other.

Abstract: A modular retroactive keyboard fitted with keys permitting to send back to the user a perception characteristic of the key. Each key is an element of an independent flat and parallelepipedic module that includes a motor, a position detector and an electric connector. Each module further includes arrangement for fixing it to the adjacent module, and the keys are connected to a central processing unit for giving them the desired response by acting on the motor and for processing the detector signals.